Forget IPOs, 'Phenture Capital' exits now controlled by pharma
This article was originally published in Scrip
Executive Summary
Venture capital firms no longer see any potential for viable exits through the public markets. Investments by VCs in new companies are now driven on the likelihood of that company being acquired by big pharma and their kind, according to a top venture capitalist. This does not bode well for start-ups with assets that fall outside of traditional pharma wish-lists.